Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All

Executive Summary

It's possible that potential risk for thromboembolic events flagged in rheumatoid arthritis studies could be managed in labeling.

Advertisement

Related Content

Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee
AbbVie's Upadacitinib Safety Appears Improved In Largest, Longest RA Study
ACR Roundup: JAK Safety Shown Across Multiple Trials
ACR Roundup: JAK Safety Shown Across Multiple Trials
ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III
Lilly Math: Subtracting Employees And Animal Health Equals Pharma Growth
Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7
Safety Issues Not Dampening AbbVie Optimism For Humira Successors
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099401

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel